Secondaries Announced 2.12.18

IPO BOUTIQUE CLIENTS and IPO BOUTIQUE SECONDARY ALERTS CLIENTS received ALL this information to their inbox on a REAL TIME basis.

If having real-time alerts for secondary offerings would be an advantage to you, inquire about a subscription today!

Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis. For example, this is not to be interpreted as a Buy recommendation in the traditional sense of adding to your stock portfolio; this is a short term (usually one day or opening trade) time period.

Company: Daseke, Inc.
Symbol: DSKE
Price: Last Trade $12.98
Trade Date: 2/15
Shares: 7.5 million
Underwriter(s): Cowen, Stifel
Co-Manager(s): Craig-Hallum Capital Group, Northland Capital
Description: They are a leading provider and consolidator of transportation and logistics solutions focused exclusively on flatbed and specialized freight in North America.
Rating = Subscription Needed

Company: Helios and Matheson Analytics Inc.
Symbol: HMNY
Price: Last Trade $7.99
Trade Date: 2/13
Shares: 13.1 million ($105 million cash raise)
Re-Offer Range: Subscription Needed
Underwriter(s): Canaccord Genuity
Co-Manager(s): Maxim Group
Description: They are a provider of information technology services and solutions, offering a range of technology platforms focusing on big data, artificial intelligence, business intelligence, social listening, and consumer-centric technology.
Rating = Subscription Needed

Company: Pacific Biosciences of California
Symbol: PACB
Price: Last Trade $2.54
Trade Date: 2/13
Shares: 12.24 million ($30 million cash raise)
Re-Offer Range: Subscription Needed
Underwriter(s): Cantor Fitzgerald
Description: Pacific Biosciences offers sequencing systems to help scientists resolve genetically complex problems.
Rating = Subscription Needed

Company: Affimed, Inc.
Symbol: AFMD
Price: Last Trade $2.45
Trade Date: 2/13
Shares: 9.2 million
Re-Offer Range: Subscription Needed
Underwriter(s): Jefferies, Wells Fargo Securities
Description: Affimed engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity.
Rating =Subscription Needed

Company: Catalyst Biosciences, Inc.
Symbol: CBIO
Price: Last Trade $35.60
Trade Date: 2/13
Shares: 2.2 million ($75 million cash raise)
Re-Offer Range: Subscription Needed
Underwriter(s): JonesTrading, Ladenburg Thalmann
Co-Manager(s): LifeSci Capital
Description: Catalyst is a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia.
Rating = Subscription Needed